Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution... see more

TSXV:WAVE - Post Discussion

Waverley Pharma Inc > Waverley Pharma Announces Sales of its Cancer Drug in EU
View:
Post by moneywinner1 on Aug 25, 2020 10:20am

Waverley Pharma Announces Sales of its Cancer Drug in EU

Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy

Comment by moneywinner1 on Aug 25, 2020 10:42am
Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy
Comment by moneywinner1 on Aug 25, 2020 8:10pm
News should be blasted again, such a huge development and no moves yet?, this is a dollar+ stock 
Comment by bigkagan on Aug 25, 2020 9:26pm
regular cancer drugs are in the tens of thousands of $$ a year, so generic versions should be in high demand due to lower prices but still provide a good margin
Comment by moneywinner1 on Aug 25, 2020 9:48pm
Yes , that is why they should blast the news again big time 
Comment by moneywinner1 on Aug 26, 2020 10:41am
This is a winner in the making now 
Comment by pinkfloyd90 on Aug 26, 2020 10:44am
yes....and its only the beginning...cant find too many stocks out there with this potential and low float and insiders holding a large percent at over double the current price..
Comment by moneywinner1 on Aug 26, 2020 10:49am
Now we need CEO to step up to get the world know of Wave . We all can easily make 1000% here 
Comment by Peytolake on Aug 26, 2020 11:08am
And why we lost 4 cents from the high yesterday? With big sales yesterday and today? We have chance of 1000% and the selling is going on? Where is the mistake, what's wrong? thanks!
Comment by moneywinner1 on Aug 26, 2020 11:13am
Some short selling and some shares are in hands of peoples trading for pennies, they all make money in a sure value stock 
Comment by Kyle12345 on Aug 26, 2020 11:33am
How do you get to 1000%
Comment by moneywinner1 on Aug 26, 2020 11:48am
You do have to sell from time to time   Accumulate free shares like from yesterday to today I have 8% more 
Comment by moneywinner1 on Aug 26, 2020 11:14am
Aug. 25, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited, has been granted marketing authorization for Pemetrexed in Spain and Bortezomib in Italy.
Comment by Peytolake on Aug 26, 2020 11:24am
We lost 5,5 Cent and we are now at 0,185$. pennypflippers??? 
Comment by pinkfloyd90 on Aug 26, 2020 11:31am
a terrific buying opp....very few stocks like this out there.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities